Autologous cultured urological tissue cells - RegenMedTX

Drug Profile

Autologous cultured urological tissue cells - RegenMedTX

Alternative Names: Neo-Bladder Augment; Neo-bladder construct - RegenMedTX; Neo-Bladder Replacement; Neo-Urinary Conduit; Urinary neo-bladder construct

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tengion
  • Developer RegenMedTX; Tengion
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Genitourinary disorders; Neurogenic bladder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Genitourinary-disorders in USA (Intralesional, Implant)
  • 01 Dec 2014 Tengion completes a phase I trial in Genitourinary disorders in USA (NCT01087697)
  • 01 Jan 2014 Tengion completes enrolment in its phase I trial for Genitourinary disorders in USA (NCT01087697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top